Paclitaxel 6mg/ml Concentrate for Solution for Infusion

DRUG2 trials

Sponsors

Replimune Inc., Cancer Trials Ireland

Conditions

Advanced MelanomaHormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or LessPatients with 1-3 positive Nodes

Phase 3

SWOG S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endrocrine Therapy +/- Chemotheraphy in Patients with 1-3 Positive Nodes Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or less

Active, not recruitingCTIS2024-516801-22-00

Cancer Trials IrelandHormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less, Patients with 1-3 positive Nodes

Start: 2012-04-26Target: 141Updated: 2025-05-20

A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3]

RecruitingCTIS2023-508612-29-00

Replimune Inc.Advanced Melanoma

Start: 2025-11-07Target: 193Updated: 2025-11-04